Drug Profile
Research programme: lysins - Bioharmony Therapeutics
Alternative Names: BH 01; BH 02; BH 03; BH 04Latest Information Update: 28 Feb 2023
Price :
$50
*
At a glance
- Originator Bioharmony Therapeutics
- Developer Bioharmony Therapeutics; Boehringer Ingelheim
- Class Antibacterials; Endolysins; Endopeptidases; Enzymes; Proteins
- Mechanism of Action Cell wall inhibitors; Peptidoglycan modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Burns; Gram-negative infections; Nosocomial infections; Pneumonia; Skin and soft tissue infections; Urinary tract infections
Most Recent Events
- 28 Feb 2023 No recent reports of development identified for research development in Nosocomial-infections(Treatment-resistant) in USA (Topical)
- 28 Jan 2022 No recent reports of development identified for preclinical development in Burns(Treatment-resistant) in USA (Topical)
- 28 Jan 2022 No recent reports of development identified for research development in Gram-negative-infections(Treatment-resistant) in USA